Rapt Therapeutics
About
Rapt is focused on the discovery and development of novel small-molecule agents to activate the immune system to eradicate cancer.
- South San Francisco,California,United States
- 101 - 250
- https://rapt.com/
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $70.50M
- Industries
- Biotechnology,Health Care,Medical,Pharmaceutical,Therapeutics
- Founded date
- Mar 4, 2015
- Number Of Employee
- 101 - 250
- Operating Status
- Active
- Stock Symbol
- nasdaq:RAPT
- Legal Name
- Rapt Therapeutics Inc.
- Also Known As
- FLX Bio
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has discovered and advanced two unique drug candidates, each targeting C-C motif chemokine receptor 4. The company’s lead oncology drug candidate, FLX475, reached the clinic in just two and a half years with its lead inflammation drug candidate, RPT193, also in the clinic. The company is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, that are in the discovery stage of development.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 17, 2022 | Post-IPO Equity | $70.50M | — | — | — | Detail |
| May 25, 2022 | Post-IPO Equity | $50M | 1 |
|
— | Detail |
| Jun 18, 2021 | Post-IPO Equity | $143.70M | — | — | — | Detail |
| Jan 1, 2020 | Post-IPO Equity | — | 1 | — | — | Detail |
| Oct 30, 2019 | IPO | $36M | — | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 11, 2022
Stairwell
|
Series B | $45M | Cyber Security | — |
|
Sep 27, 2022
Kumo.AI
|
Series B | $18M | Artificial Intelligence | — |
|
Aug 9, 2022
CreatorDAO
|
Seed | $20M | Cryptocurrency | — |
|
Jun 28, 2022
Tenet
|
Seed | $18M | FinTech | — |
|
Jun 1, 2022
WorkOS
|
Series B | $80M | Developer APIs | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Post-IPO Equity |
Solasta Ventures
|
— | Post-IPO Equity |
Kleiner Perkins
|
— | Series C |
Regents of the University of California
|
— | Series C |
The Column Group
|
— | Series C |
Topspin Partners
|
— | Series C |
Celgene
|
— | Series C |
GV
|
— | Series C |
Employee Profiles
